A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(6 sites)

Hong Kong

Queen Mary Hospital, Hong Kong

Japan

National Cancer Center Hospital East, Kashiwa, Chiba

Ehime University Hospital, Tōon, Ehime

Kindai University Hospital, Sakai, Osaka

Niigata Cancer Center Hospital, Niigata

Taiwan

Show Chwan Memorial Hospital, Changhua